0
Obstructive Lung Diseases: COPD II |

Effects of Low-Dose and Long-Term Treatment With Erythromycin on IL-17, IL-23 in Peripheral Blood and Induced Sputum in Patients With Stable Chronic Obstructive Pulmonary Disease FREE TO VIEW

Caimei Tan, MD; Huijuan Huang, MD; Jianquan Zhang, MD; Zhiyi He, PhD; Xiaoning Zhong, PhD; Jin Bai, PhD
Author and Funding Information

First Affiliated Hospital of Guangxi Medical University, Nanning, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A387. doi:10.1016/j.chest.2016.02.402
Text Size: A A A
Published online

SESSION TITLE: COPD II

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: To study the effects of low-dose and long-term treatment with erythromycin on interleukin-17 (IL-17), interleukin-23 (IL-23) both in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease.

METHODS: We performed a randomized double-blind placebo-controlled trail. The stable COPD out-patients (GOLD Ⅱ~Ⅳ) in the First Affiliated Hospital of Guangxi Medical University recruited were randomly divided into placebo-control group and erythromycin group, the later divided into Group A (additively 12-month treatment with erythromycin, n=9) and Group B (additively 6-month treatment with erythromycin, then 6-month followed up, n=9). The inflammatory cells in induced sputum, pulmonary function, six-minute walk distance (6MWD) were observed and the concentrations of IL-17, IL-23 in both peripheral blood and induced sputum were measured by enzyme-linked immuno sorbent assay (ELISA).

RESULTS: After treatment with erythromycin, the concentrations of IL17 and IL23 in induced sputum decreased significantly in group A and group B compared with placebo-treated group (p<.001 and p<.001, respectively). A similar reduction in the concentrations of IL17 and IL23 in serum was also observed in group A and group B compared with placebo-treated group (p<.001 and p<.001, respectively). The concentrations of sputum IL17 (p=.20 and p=.18, respectively), sputum IL23 (p=.53 and p>.99), serum IL17 (p values all >0.99) and serum IL23 (p=.53 and p>0.99, respectively) showed no significantly differences after erythromycin withdrew at months 9 and 12 in group B compared with placebo-treated group while a significantly reduction in the concentrations of IL17 and IL23 both in induced sputum and serum at months 9 and 12 in group A was observed compared with placebo-treated group (p values all <.05). In addition, an increase in the six minute-walk distance (6MWD) was observed at months 6, 9 and 12 in group A and months 6 in group B (p values all >.05) compared with placebo-treated group.

CONCLUSIONS: Erythromycin treatment showed beneficial effects on reduction of airway inflammation. Erythromycin may inhibit the Th17-mediated airway inflammation which may be one of the anti-inflammation mechanisms. For 12 months treatment may be better. Moreover, it can improve the exercise capacity of patients with COPD to a certain extent.

CLINICAL IMPLICATIONS: To further study the mechanism of the erythromycin treatment on COPD, and provide a new ideas for erythromycin clinical trepary on COPD.

DISCLOSURE: The following authors have nothing to disclose: Caimei Tan, Huijuan Huang, Jianquan Zhang, Zhiyi He, Xiaoning Zhong, Jin Bai

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543